Search

Your search keyword '"Morgagni P"' showing total 334 results
Start Over Author "Morgagni P"
334 results on '"Morgagni P"'

1. Genomic events stratifying prognosis of early gastric cancer

Author

Molinari, Chiara, Solaini, Leonardo, Rebuzzi, Francesca, Tedaldi, Gianluca, Angeli, Davide, Petracci, Elisabetta, Prascevic, Dusan, Ewald, Jan, Rahm, Erhard, Canale, Matteo, Giovanni, Martinelli, Tomezzoli, Anna, Bencivenga, Maria, Ambrosio, Maria Raffaella, Marrelli, Daniele, Morgagni, Paolo, Ercolani, Giorgio, Ulivi, Paola, and Saragoni, Luca

Published
2024
Full Text
View/download PDF

2. International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape: Bertinoro Workshop, November 2022

Author

Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han-Kwang, Roviello, Franco, and de Manzoni, Giovanni

Published
2024
Full Text
View/download PDF

3. Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape

Author

Morgagni, Paolo, Bencivenga, Maria, Carneiro, Fatima, Cascinu, Stefano, Derks, Sarah, Di Bartolomeo, Maria, Donohoe, Claire, Eveno, Clarisse, Gisbertz, Suzanne, Grimminger, Peter, Gockel, Ines, Grabsch, Heike, Kassab, Paulo, Langer, Rupert, Lonardi, Sara, Maltoni, Marco, Markar, Sheraz, Moehler, Markus, Marrelli, Daniele, Mazzei, Maria Antonietta, Melisi, Davide, Milandri, Carlo, Moenig, Paul Stefan, Mostert, Bianca, Mura, Gianni, Polkowski, Wojciech, Reynolds, John, Saragoni, Luca, Van Berge Henegouwen, Mark I., Van Hillegersberg, Richard, Vieth, Michael, Verlato, Giuseppe, Torroni, Lorena, Wijnhoven, Bas, Tiberio, Guido Alberto Massimo, Yang, Han-Kwang, Roviello, Franco, and de Manzoni, Giovanni

Published
2024
Full Text
View/download PDF

5. Advanced Gastric Cancer: Single-Center Experience

Author

Massimo Framarini, Fabrizio D’Acapito, Daniela Di Pietrantonio, Francesca Tauceri, Giovanni Vittimberga, Leonardo Solaini, Giulia Elena Cantelli, Giulia Marchetti, Paolo Morgagni, and Giorgio Ercolani

Subjects
advanced gastric cancer, HIPEC, hyperthermic intraperitoneal chemotherapy, Surgery, RD1-811
Abstract

Gastric cancer (GC) is the fifth most diagnosed cancer, but it is the third leading cause of cancer death worldwide. Despite the likelihood of gastric cancer metastasizing to the peritoneum, optimal management strategies for this population remain undefined. We carried out a retrospective analysis to present our findings on patients with advanced gastric cancer (AGC) with peritoneal metastases (CP) who underwent neoadjuvant chemotherapy followed by gastrectomy + hyperthermic intraperitoneal chemotherapy (HIPEC). To better understand the data, we compared these patients with AGC patients without CP who were treated with neoadjuvant chemotherapy and surgery, as well as with another group of patients who underwent upfront surgery. Patients who undergo surgery and HIPEC achieve a higher survival rate than patients in the literature who undergo only palliative chemotherapy with a median overall survival of 28 months with a low incidence of major complications.

Published
2024
Full Text
View/download PDF

6. Preoperative multidetector-row computed tomography scan staging for lymphatic gastric cancer spread

Author

Morgagni Paolo, Petrella Enrico, Basile Barbara, Mami Alberto, Soro Augusto, Gardini Andrea, Calzolari Filippo, Garcea Domenico, and Bertocco Mauro

Subjects
MDCT staging, Gastric cancer, Lymph-node diffusion, Preoperative setting, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Multidetector-row computed tomography (MDCT) is commonly used to stage patients with gastric cancer, even though the technique often shows low specificity for lymph-node involvement. Methods In this study, 111 patients with gastric cancer who consecutively underwent MDCT scan followed by radical surgical treatment at our hospital were retrospectively evaluated. Results In total, 3632 lymph nodes from 643 lymphatic stations were studied and then correlated with radiological features. Lymph-node size was not always associated with infiltration. Of the 261 lymph-node stations that were not radiologically detected, 60 (22.9%) were infiltrated. There were 108 stations with lymph nodes larger than 10 mm seen on MDCT, of which 67 (62%) had lymphatic invasion. The sensitivity was 32.6%, specificity 90.6%, positive predictive value 62.0%, negative predictive value 74.2%, and accuracy 72.1%. When three lymph nodes, at least one of which was larger than 10 mm, were detected in the same station, infiltration was confirmed with 99% specificity in 93.8% of patients. Moreover, all of the 13 patients in whom three lymph nodes larger than 10 mm were detected in different neighboring stations had lymphatic invasion. Conclusions Although presence of lymph nodes greater than 10 mm in size is not, in itself, sufficient to confirm lymphatic invasion, nodal involvement can be hypothesized when associated images are detected by MDCT.

Published
2012
Full Text
View/download PDF

8. Clinical outcomes of patients with complicated post-operative course after gastrectomy for cancer: a GIRCG study using the GASTRODATA registry

Author

Baiocchi, Gian Luca, Giacopuzzi, Simone, Vittimberga, Giovanni, De Pascale, Stefano, Pastorelli, Elisabetta, Gelmini, Roberta, Viganò, Jacopo, Graziosi, Luigina, Vagliasindi, Alessio, Rosa, Fausto, Steccanella, Francesca, Demartini, Paolo, Reddavid, Rossella, Berselli, Mattia, Elmore, Ugo, Romario, Uberto Fumagalli, Degiuli, Maurizio, Morgagni, Paolo, Marrelli, Daniele, D’Ugo, Domenico, Rosati, Riccardo, and De Manzoni, Giovanni

Published
2023
Full Text
View/download PDF

9. Perforated gastric carcinoma: a report of 10 cases and review of the literature

Author

Morgagni Paolo, Pedrazzani Corrado, De Manzoni Giovanni, Marrelli Daniele, Rossi Simone, Roviello Franco, Corso Giovanni, and Pinto Enrico

Subjects
Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Perforation is a rare complication of gastric carcinoma, accounting for less than 1% of all gastric cancer cases. The aim of the present study is to evaluate the prognostic value of perforation and to point out the surgical treatment options. Methods A total of 10 patients with perforated gastric carcinoma were retrospectively reviewed among 2564 consecutive cases of gastric cancer operated in three Centers belonging to the Italian Research Group for Gastric Cancer. The clinicopathological features including tumor stage and survival were analyzed and compared to literature data. Results Incidence rate was 0.39%. All patients underwent emergency surgery, being performed gastrectomy in 6 patients (mortality 17%) and repair surgery in 4 patients (mortality 75%). The survival of patients was related to the stage of the disease, with 2 long-survival cases. Conclusion Perforation usually occurs in advanced stages of gastric cancer; nevertheless surgeons should not be always discouraged from a radical treatment of perforated gastric cancer, since perforation even occurs in early stages and seems not to be a negative prognostic factor itself. When possible, emergency gastrectomy should be performed, leaving repair surgery for unresectable tumors. A two-stage treatment is a good treatment option for frail patients with resectable tumors.

Published
2006
Full Text
View/download PDF

10. Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM)

Author

Mazzei, Maria Antonietta, Bagnacci, Giulio, Gentili, Francesco, Capitoni, Iacopo, Mura, Gianni, Marrelli, Daniele, Petrioli, Roberto, Brunese, Luca, Cappabianca, Salvatore, Catarci, Marco, Degiuli, Maurizio, De Manzoni, Giovanni, De Prizio, Marco, Donini, Annibale, Romario, Uberto Fumagalli, Funicelli, Luigi, Laghi, Andrea, Minetti, Giuseppe, Morgagni, Paolo, Petrella, Enrico, Pittiani, Frida, Rausei, Stefano, Romanini, Laura, Rosati, Riccardo, Ianora, Amato Antonio Stabile, Tiberio, Guido A. M., Volterrani, Luca, Roviello, Franco, and Grassi, Roberto

Published
2022
Full Text
View/download PDF

11. Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer

Author

Manlio Monti, Andrea Prochowski Iamurri, David Bianchini, Chiara Gallio, Luca Esposito, Daniela Montanari, Silvia Ruscelli, Chiara Molinari, Flavia Foca, Alessandro Passardi, Giovanni Vittimberga, Paolo Morgagni, and Giovanni Luca Frassineti

Subjects
locally advanced gastric cancer, neoadjuvant, perioperative chemotherapy, compliance, pre-treatment indicators, Nutrition. Foods and food supply, TX341-641
Abstract

Background and aims: Perioperative treatment is currently the gold standard approach in Europe for locally advanced gastric cancer (GC). Unfortunately, the phenomenon of patients dropping out of treatment has been frequently observed. The primary aims of this study were to verify if routine blood parameters, inflammatory response markers, sarcopenia, and the depletion of adipose tissues were associated with compliance to neoadjuvant/perioperative chemotherapy. Methods and study design: Blood samples were considered before the first and second cycles of chemotherapy. Sarcopenia and adipose indices were calculated with a CT scan before starting chemotherapy and before surgery. Odds ratios (OR) from univariable and multivariable models were calculated with a 95% confidence interval (95% CI). Results: A total of 84 patients with locally advanced GC were identified between September 2010 and January 2021. Forty-four patients (52.4%) did not complete the treatment according to the number of cycles planned/performed. Eight patients (9.5%) decided to suspend chemotherapy, seven patients (8.3%) discontinued because of clinical decisions, fourteen patients (16.7%) discontinued because of toxicity and fifteen patients (17.9%) discontinued for miscellaneous causes. Seventy-nine (94%) out of eighty-four patients underwent gastrectomy, with four patients having surgical complications, which led to a suspension of treatment. Sarcopenia was present in 38 patients (50.7%) before chemotherapy began, while it was present in 47 patients (60%) at the CT scan before the gastrectomy. At the univariable analysis, patients with basal platelet to lymphocyte ratio (PLR) ≥ 152 (p = 0.017) and a second value of PLR ≥ 131 (p = 0.007) were more frequently associated with an interruption of chemotherapy. Patients with increased PLR (p = 0.034) compared to the cut-off were associated with an interruption of chemotherapy, while patients with increased monocytes between the first and second cycles were associated with a lower risk of treatment interruption (p = 0.006); patients who underwent 5-fluorouracil plus cisplatin or oxaliplatin had a higher risk of interruption (p = 0.016) compared to patients who underwent a 5-fluorouracil plus leucovorin, oxaliplatin and docetaxel (FLOT) regimen. The multivariable analysis showed a higher risk of interruption for patients who had higher values of PLR compared to the identified cut-off both at pretreatment and second-cycle evaluation (OR: 5.03; 95% CI: 1.34–18.89; p = 0.017) as well as for patients who had a lower PLR than the identified cut-off at pretreatment evaluation and had a higher PLR value than the cut-off at the second cycle (OR: 4.64; 95% CI: 1.02–21.02; p = 0.047). Becker regression was neither affected by a decrease of sarcopenia ≥ 5% (p = 0.867) nor by incomplete compliance with chemotherapy (p = 0.281). Conclusions: Changes in PLR values which tend to increase more than the cut-off seem to be an immediate indicator of incomplete compliance with neoadjuvant/perioperative treatment. Fat loss and sarcopenia do not appear to be related to compliance. More information is needed to reduce the causes of interruption.

Published
2023
Full Text
View/download PDF

12. Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis

Author

Molinari, Chiara, Tedaldi, Gianluca, Rebuzzi, Francesca, Morgagni, Paolo, Capelli, Laura, Ravaioli, Sara, Tumedei, Maria Maddalena, Scarpi, Emanuela, Tomezzoli, Anna, Bernasconi, Riccardo, Ambrosio, Maria Raffaella, D’Ignazio, Alessia, Solaini, Leonardo, Limarzi, Francesco, Ercolani, Giorgio, Martinelli, Giovanni, Ulivi, Paola, and Saragoni, Luca

Published
2021
Full Text
View/download PDF

13. Looking for a strategy in treating peritoneal gastric cancer carcinomatosis: an Italian multicenter Gastric Cancer Research group’s analysis

Author

Graziosi, Luigina, Marino, Elisabetta, Bencivenga, Maria, D’Ignazio, Alessia, Solaini, Leonardo, Ministrini, Silvia, Caprioli, Michela, Sacco, Michele, Marrelli, Daniele, Mura, Gianni, Degiuli, Maurizio, Morgagni, Paolo, Tiberio, Guido Alberto Massimo, De Manzoni, Giovanni, Roviello, Franco, and Donini, Annibale

Published
2021
Full Text
View/download PDF

15. International consensus on a complications list after gastrectomy for cancer

Author

Baiocchi, Gian Luca, Giacopuzzi, Simone, Marrelli, Daniele, Reim, Daniel, Piessen, Guillaume, Matos da Costa, Paulo, Reynolds, John V., Meyer, Hans-Joachim, Morgagni, Paolo, Gockel, Ines, Lara Santos, Lucio, Jensen, Lone Susanne, Murphy, Thomas, Preston, Shaun R., Ter-Ovanesov, Mikhail, Fumagalli Romario, Uberto, Degiuli, Maurizio, Kielan, Wojciech, Mönig, Stefan, Kołodziejczyk, Piotr, Polkowski, Wojciech, Hardwick, Richard, Pera, Manuel, Johansson, Jan, Schneider, Paul M., de Steur, Wobbe O., Gisbertz, Suzanne S., Hartgrink, Henk, van Sandick, Joanna W., Portolani, Nazario, Hölscher, Arnulf H., Botticini, Maristella, Roviello, Franco, Mariette, Christophe, Allum, William, and De Manzoni, Giovanni

Published
2019
Full Text
View/download PDF

16. Open versus laparoscopic gastrectomy for advanced gastric cancer: a propensity score matching analysis of survival in a western population—on behalf of the Italian Research Group for Gastric Cancer

Author

Lombardi, P, Bernasconi, D, Baiocchi, G, Berselli, M, Biondi, A, Castoro, C, Catarci, M, Degiuli, M, Fumagalli Romario, U, Giacopuzzi, S, Marchesi, F, Marrelli, D, Mazzola, M, Molfino, S, Olmi, S, Rausei, S, Rosa, F, Rosati, R, Roviello, F, Santi, S, Solaini, L, Staderini, F, Vigano, J, Ferrari, G, Agnes, A, Alfieri, S, Alloggio, M, Bencivenga, M, Benedetti, M, Bottari, A, Cianchi, F, Cocozza, E, Dalmonte, G, De Martini, P, De Pascale, S, Desio, M, Emiliani, G, Ercolani, G, Galli, F, Garosio, I, Giani, A, Gualtierotti, M, Marano, L, Morgagni, P, Peri, A, Puccetti, F, Reddavid, R, Uccelli, M, Lombardi P. M., Bernasconi D., Baiocchi G. L., Berselli M., Biondi A., Castoro C., Catarci M., Degiuli M., Fumagalli Romario U., Giacopuzzi S., Marchesi F., Marrelli D., Mazzola M., Molfino S., Olmi S., Rausei S., Rosa F., Rosati R., Roviello F., Santi S., Solaini L., Staderini F., Vigano J., Ferrari G., Agnes A., Alfieri S., Alloggio M., Bencivenga M., Benedetti M., Bottari A., Cianchi F., Cocozza E., Dalmonte G., De Martini P., De Pascale S., Desio M., Emiliani G., Ercolani G., Galli F., Garosio I., Giani A., Gualtierotti M., Marano L., Morgagni P., Peri A., Puccetti F., Reddavid R., Uccelli M., Lombardi, P, Bernasconi, D, Baiocchi, G, Berselli, M, Biondi, A, Castoro, C, Catarci, M, Degiuli, M, Fumagalli Romario, U, Giacopuzzi, S, Marchesi, F, Marrelli, D, Mazzola, M, Molfino, S, Olmi, S, Rausei, S, Rosa, F, Rosati, R, Roviello, F, Santi, S, Solaini, L, Staderini, F, Vigano, J, Ferrari, G, Agnes, A, Alfieri, S, Alloggio, M, Bencivenga, M, Benedetti, M, Bottari, A, Cianchi, F, Cocozza, E, Dalmonte, G, De Martini, P, De Pascale, S, Desio, M, Emiliani, G, Ercolani, G, Galli, F, Garosio, I, Giani, A, Gualtierotti, M, Marano, L, Morgagni, P, Peri, A, Puccetti, F, Reddavid, R, Uccelli, M, Lombardi P. M., Bernasconi D., Baiocchi G. L., Berselli M., Biondi A., Castoro C., Catarci M., Degiuli M., Fumagalli Romario U., Giacopuzzi S., Marchesi F., Marrelli D., Mazzola M., Molfino S., Olmi S., Rausei S., Rosa F., Rosati R., Roviello F., Santi S., Solaini L., Staderini F., Vigano J., Ferrari G., Agnes A., Alfieri S., Alloggio M., Bencivenga M., Benedetti M., Bottari A., Cianchi F., Cocozza E., Dalmonte G., De Martini P., De Pascale S., Desio M., Emiliani G., Ercolani G., Galli F., Garosio I., Giani A., Gualtierotti M., Marano L., Morgagni P., Peri A., Puccetti F., Reddavid R., and Uccelli M.

Abstract

Background: Oncologic outcomes after laparoscopic gastrectomy for advanced gastric cancer in the West have been poorly investigated. The aim of the present study was to compare survival outcomes in patients undergoing curative-intent laparoscopic and open gastrectomy for advanced gastric cancer in several centres belonging to the Italian Research Group for Gastric Cancer. Methods: Data of patients operated between 2015 and 2018 were retrospectively analysed. Propensity Score Matching was performed to balance baseline characteristics of patients undergoing laparoscopic and open gastrectomy. The primary endpoint was 3-year overall survival. Secondary endpoints were 3-year disease-free survival and short-term outcomes. Multivariable regression analyses for survival were conducted. Results: Data were retrieved from 20 centres. Of the 717 patients included, 438 patients were correctly matched, 219 per group. The 3-year overall survival was 73.6% and 68.7% in the laparoscopic and open group, respectively (p = 0.40). When compared with open gastrectomy, laparoscopic gastrectomy showed comparable 3-year disease-free survival (62.8%, vs 58.9%, p = 0.40), higher rate of return to intended oncologic treatment (56.9% vs 40.2%, p = 0.001), similar 30-day morbidity/mortality. Prognostic factors for survival were ASA Score ≥ 3, age-adjusted Charlson Comorbidity Index ≥ 5, lymph node ratio ≥ 0.15, p/ypTNM Stage III and return to intended oncologic treatment. Conclusions: Laparoscopic gastrectomy for advanced gastric cancer offers similar rates of survival when compared to open gastrectomy, with higher rates of return to intended oncologic treatment. ASA score, age-adjusted Charlson Comorbidity Index, lymph node ratio, return to intended oncologic treatment and p/ypTNM Stage, but not surgical approach, are prognostic factors for survival.

Published
2022

17. Current practice on the use of prophylactic drain after gastrectomy in Italy: the Abdominal Drain in Gastrectomy (ADiGe) survey

Author

Mengardo, V, Weindelmayer, J, Veltri, A, Giacopuzzi, S, Torroni, L, de Manzoni, G, Agresta, F, Alfieri, R, Alfieri, S, Antonacci, N, Baiocchi, G, Bencini, L, Bencivenga, M, Benedetti, M, Berselli, M, Biondi, A, Capolupo, G, Carboni, F, Casadei, R, Casella, F, Catarci, M, Cerri, P, Chiari, D, Cocozza, E, Colombo, G, Cozzaglio, L, Dalmonte, G, Degiuli, M, De Luca, M, De Luca, R, De Manzini, N, De Pasqual, C, De Pascale, S, De Ruvo, N, Di Cosmo, M, Di Leo, A, Di Paola, M, Elio, A, Ferrara, F, Ferrari, G, Fiscon, V, Fumagalli, U, Garulli, G, Gennai, A, Gentile, I, Germani, P, Gualtierotti, M, Guerini, F, Gurrado, A, Inama, M, La Torre, F, Laterza, E, Losurdo, P, Macri, A, Marano, A, Marano, L, Marchesi, F, Marino, F, Massani, M, Menghi, R, Milone, M, Molfino, S, Montuori, M, Moretto, G, Morgagni, P, Morpurgo, E, Abdallah, M, Nespoli, L, Olmi, S, Palaia, R, Pallabazer, G, Parise, P, Pasculli, A, Pericoli Ridolfini, M, Pesce, A, Pinotti, E, Pisano, M, Poiasina, E, Postiglione, V, Rausei, S, Rella, A, Rosa, F, Rosati, R, Rossi, G, Rossit, L, Rovatti, M, Ruspi, L, Sacco, L, Saladino, E, Sansonetti, A, Sartori, A, Scaglione, D, Scaringi, S, Schoenthaler, C, Sena, G, Simone, M, Solaini, L, Strignano, P, Tartaglia, N, Testa, S, Testini, M, Tiberio, G, Treppiedi, E, Vagliasindi, A, Valmasoni, M, Vigano, J, Zanchettin, G, Zanoni, A, Zardini, C, Zerbinati, A, Mengardo V., Weindelmayer J., Veltri A., Giacopuzzi S., Torroni L., de Manzoni G., Agresta F., Alfieri R., Alfieri S., Antonacci N., Baiocchi G. L., Bencini L., Bencivenga M., Benedetti M., Berselli M., Biondi A., Capolupo G. T., Carboni F., Casadei R., Casella F., Catarci M., Cerri P., Chiari D., Cocozza E., Colombo G., Cozzaglio L., Dalmonte G., Degiuli M., De Luca M., De Luca R., De Manzini N., De Pasqual C. A., De Pascale S., De Ruvo N., Di Cosmo M., Di Leo A., Di Paola M., Elio A., Ferrara F., Ferrari G., Fiscon V., Fumagalli U., Garulli G., Gennai A., Gentile I., Germani P., Gualtierotti M., Guerini F., Gurrado A., Inama M., La Torre F., Laterza E., Losurdo P., Macri A., Marano A., Marano L., Marchesi F., Marino F., Massani M., Menghi R., Milone M., Molfino S., Montuori M., Moretto G., Morgagni P., Morpurgo E., Abdallah M., Nespoli L., Olmi S., Palaia R., Pallabazer G., Parise P., Pasculli A., Pericoli Ridolfini M., Pesce A., Pinotti E., Pisano M., Poiasina E., Postiglione V., Rausei S., Rella A., Rosa F., Rosati R., Rossi G., Rossit L., Rovatti M., Ruspi L., Sacco L., Saladino E., Sansonetti A., Sartori A., Scaglione D., Scaringi S., Schoenthaler C., Sena G., Simone M., Solaini L., Strignano P., Tartaglia N., Testa S., Testini M., Tiberio G. A. M., Treppiedi E., Vagliasindi A., Valmasoni M., Vigano J., Zanchettin G., Zanoni A., Zardini C., Zerbinati A., Mengardo, V, Weindelmayer, J, Veltri, A, Giacopuzzi, S, Torroni, L, de Manzoni, G, Agresta, F, Alfieri, R, Alfieri, S, Antonacci, N, Baiocchi, G, Bencini, L, Bencivenga, M, Benedetti, M, Berselli, M, Biondi, A, Capolupo, G, Carboni, F, Casadei, R, Casella, F, Catarci, M, Cerri, P, Chiari, D, Cocozza, E, Colombo, G, Cozzaglio, L, Dalmonte, G, Degiuli, M, De Luca, M, De Luca, R, De Manzini, N, De Pasqual, C, De Pascale, S, De Ruvo, N, Di Cosmo, M, Di Leo, A, Di Paola, M, Elio, A, Ferrara, F, Ferrari, G, Fiscon, V, Fumagalli, U, Garulli, G, Gennai, A, Gentile, I, Germani, P, Gualtierotti, M, Guerini, F, Gurrado, A, Inama, M, La Torre, F, Laterza, E, Losurdo, P, Macri, A, Marano, A, Marano, L, Marchesi, F, Marino, F, Massani, M, Menghi, R, Milone, M, Molfino, S, Montuori, M, Moretto, G, Morgagni, P, Morpurgo, E, Abdallah, M, Nespoli, L, Olmi, S, Palaia, R, Pallabazer, G, Parise, P, Pasculli, A, Pericoli Ridolfini, M, Pesce, A, Pinotti, E, Pisano, M, Poiasina, E, Postiglione, V, Rausei, S, Rella, A, Rosa, F, Rosati, R, Rossi, G, Rossit, L, Rovatti, M, Ruspi, L, Sacco, L, Saladino, E, Sansonetti, A, Sartori, A, Scaglione, D, Scaringi, S, Schoenthaler, C, Sena, G, Simone, M, Solaini, L, Strignano, P, Tartaglia, N, Testa, S, Testini, M, Tiberio, G, Treppiedi, E, Vagliasindi, A, Valmasoni, M, Vigano, J, Zanchettin, G, Zanoni, A, Zardini, C, Zerbinati, A, Mengardo V., Weindelmayer J., Veltri A., Giacopuzzi S., Torroni L., de Manzoni G., Agresta F., Alfieri R., Alfieri S., Antonacci N., Baiocchi G. L., Bencini L., Bencivenga M., Benedetti M., Berselli M., Biondi A., Capolupo G. T., Carboni F., Casadei R., Casella F., Catarci M., Cerri P., Chiari D., Cocozza E., Colombo G., Cozzaglio L., Dalmonte G., Degiuli M., De Luca M., De Luca R., De Manzini N., De Pasqual C. A., De Pascale S., De Ruvo N., Di Cosmo M., Di Leo A., Di Paola M., Elio A., Ferrara F., Ferrari G., Fiscon V., Fumagalli U., Garulli G., Gennai A., Gentile I., Germani P., Gualtierotti M., Guerini F., Gurrado A., Inama M., La Torre F., Laterza E., Losurdo P., Macri A., Marano A., Marano L., Marchesi F., Marino F., Massani M., Menghi R., Milone M., Molfino S., Montuori M., Moretto G., Morgagni P., Morpurgo E., Abdallah M., Nespoli L., Olmi S., Palaia R., Pallabazer G., Parise P., Pasculli A., Pericoli Ridolfini M., Pesce A., Pinotti E., Pisano M., Poiasina E., Postiglione V., Rausei S., Rella A., Rosa F., Rosati R., Rossi G., Rossit L., Rovatti M., Ruspi L., Sacco L., Saladino E., Sansonetti A., Sartori A., Scaglione D., Scaringi S., Schoenthaler C., Sena G., Simone M., Solaini L., Strignano P., Tartaglia N., Testa S., Testini M., Tiberio G. A. M., Treppiedi E., Vagliasindi A., Valmasoni M., Vigano J., Zanchettin G., Zanoni A., Zardini C., and Zerbinati A.

Abstract

Evidence against the use of prophylactic drain after gastrectomy are increasing and ERAS guidelines suggest the benefit of drain avoidance. Nevertheless, it is unclear whether this practice is still widespread. We conducted a survey among Italian surgeons through the Italian Gastric Cancer Research Group and the Polispecialistic Society of Young Surgeons, aiming to understand the current use of prophylactic drain. A 28-item questionnaire-based survey was developed to analyze the current practice and the individual opinion about the use of prophylactic drain after gastrectomy. Groups based on age, experience and unit volume were separately analyzed. Response of 104 surgeons from 73 surgical units were collected. A standardized ERAS protocol for gastrectomy was applied by 42% of the respondents. Most of the surgeons, regardless of age, experience, or unit volume, declared to routinely place one or more drain after gastrectomy. Only 2 (1.9%) and 7 surgeons (6.7%) belonging to high volume units, do not routinely place drains after total and subtotal gastrectomy, respectively. More than 60% of the participants remove the drain on postoperative day 4–6 after performing an assessment of the anastomosis integrity. Interestingly, less than half of the surgeons believe that drain is the main tool for leak management, and this percentage further drops among younger surgeons. On the other hand, drain’s role seems to be more defined for duodenal stump leak treatment, with almost 50% of the surgeons recognizing its importance. Routine use of prophylactic drain after gastrectomy is still a widespread practice even if younger surgeons are more persuaded that it could not be advantageous.

Published
2022

19. Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer

Author

Gianluca Tedaldi, Chiara Molinari, Celina São José, Rita Barbosa-Matos, Ana André, Rita Danesi, Valentina Arcangeli, Mila Ravegnani, Luca Saragoni, Paolo Morgagni, Francesca Rebuzzi, Matteo Canale, Sara Pignatta, Elisa Ferracci, Giovanni Martinelli, Guglielmina Nadia Ranzani, Carla Oliveira, Daniele Calistri, and Paola Ulivi

Subjects
gastric cancer, CDH1 gene, DNA methylation, regulatory regions, genetic predisposition, Next-Generation Sequencing, Medicine, Pharmacy and materia medica, RS1-441
Abstract

E-cadherin is a key player in gastric cancer (GC) and germline alterations of CDH1, its encoding gene, are responsible for Hereditary Diffuse Gastric Cancer (HDGC) syndrome. This study aimed at elucidating the role of genetic variants and DNA methylation of CDH1 promoter and enhancers in the regulation of gene expression. For this purpose, we analyzed genetic variants of the CDH1 gene through Next-Generation Sequencing (NGS) in a series of GC cell lines (NCI-N87, KATO-III, SNU-1, SNU-5, GK2, AKG, KKP) and the corresponding CDH1 expression levels. By bisulfite genomic sequencing, we analyzed the methylation status of CDH1 regulatory regions in 8 GC cell lines, in a series of 13 sporadic GC tissues and in a group of 20 HDGC CDH1-negative patients and 6 healthy controls. The NGS analysis on CDH1 coding and regulatory regions detected genetic alterations in 3 out of 5 GC cell lines lacking functional E-cadherin. CDH1 regulatory regions showed different methylation patterns in patients and controls, GC cell lines and GC tissues, expressing different E-cadherin levels. Our results showed that alterations in terms of genetic variants and DNA methylation patterns of both promoter and enhancers are associated with CDH1 expression levels and have a role in its regulation.

Published
2021
Full Text
View/download PDF

20. Textbook Oncological Outcome in European GASTRODATA.

Author

Sędłak, Katarzyna, Rawicz-Pruszyński, Karol, Mlak, Radosław, Van Sandick, Johanna, Gisbertz, Suzanne, Pera, Manuel, Cero, Mariagiulia Dal, Baiocchi, Gian Luca, Celotti, Andrea, Morgagni, Paolo, Vittimberga, Giovani, Hoelscher, Arnulf, Moenig, Stefan, Kołodziejczyk, Piotr, and Richter, Piotr

Abstract

Objective: To assess the rate of textbook outcome (TO) and textbook oncological outcome (TOO) in the European population based on the GASTRODATA registry. Background: TO is a composite parameter assessing surgical quality and strongly correlates with improved overall survival. Following the standard of treatment for locally advanced gastric cancer, TOO was proposed as a quality and optimal multimodal treatment parameter. Methods: TO was achieved when all the following criteria were met: no intraoperative complications, radical resection according to the surgeon, pR0 resection, retrieval of at least 15 lymph nodes, no severe postoperative complications, no reintervention, no admission to the intensive care unit, no prolonged length of stay, no postoperative mortality and no hospital readmission. TOO was defined as TO with the addition of perioperative chemotherapy compliance. Results: Of the 2558 patients, 1700 were included in the analysis. TO was achieved in 1164 (68.5%) patients. The use of neoadjuvant chemotherapy [odds ratio (OR) = 1.33, 95% CI: 1.04--1.70] and D2 or D2+ lymphadenectomy (OR = 1.55, 95% CI: 1.15--2.10) had a positive impact on TO achievement. Older age (OR = 0.73, 95% CI: 0.54--0.94), pT3/4 (OR = 0.79, 95% CI: 0.63--0.99), ASA 3/4 (OR = 0.68, 95% CI: 0.54--0.86) and total gastrectomy (OR = 0.56, 95% CI: 0.45--0.70), had a negative impact on TO achievement. TOO was achieved in 388 (22.8%) patients. Older age (OR = 0.37, 95% CI: 0.27--0.53), pT3 or pT4 (OR = 0.52, 95% CI: 0.39--0.69), and ASA 3 or 4 (OR = 0.58, 95% CI: 0.43--0.79) had a negative impact on TOO achievement. Conclusions: Despite successively improved surgical outcomes, stageappropriate chemotherapy in adherence to the current guidelines for multimodal treatment of gastric cancer remains poor. Further implementation of oncologic quality metrics should include greater emphasis on perioperative chemotherapy and adequate lymphadenectomy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Complications after gastrectomy for cancer: Italian perspective

Author

Baiocchi, Gian Luca, Giacopuzzi, Simone, Marrelli, Daniele, Bencivenga, Maria, Morgagni, Paolo, Rosa, Fausto, Berselli, Mattia, Orsenigo, Elena, Cananzi, Ferdinando, Tiberio, Guido, Rausei, Stefano, Cozzaglio, Luca, Degiuli, Maurizio, Di Leo, Alberto, Fumagalli, Uberto, Portolani, Nazario, Rosati, Riccardo, Roviello, Franco, De Manzoni, Giovanni, and On behalf of the Italian Research Group for Gastric Cancer (GIRCG)

Published
2017
Full Text
View/download PDF

23. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015

Author

De Manzoni, Giovanni, Marrelli, Daniele, Baiocchi, Gian Luca, Morgagni, Paolo, Saragoni, Luca, Degiuli, Maurizio, Donini, Annibale, Fumagalli, Uberto, Mazzei, Maria Antonietta, Pacelli, Fabio, Tomezzoli, Anna, Berselli, Mattia, Catalano, Filippo, Di Leo, Alberto, Framarini, Massimo, Giacopuzzi, Simone, Graziosi, Luigina, Marchet, Alberto, Marini, Mario, Milandri, Carlo, Mura, Gianni, Orsenigo, Elena, Quagliuolo, Vittorio, Rausei, Stefano, Ricci, Riccardo, Rosa, Fausto, Roviello, Giandomenico, Sansonetti, Andrea, Sgroi, Giovanni, Tiberio, Guido Alberto Massimo, Verlato, Giuseppe, Vindigni, Carla, Rosati, Riccardo, and Roviello, Franco

Published
2017
Full Text
View/download PDF

25. Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience

Author

Rosa, Fausto, Marrelli, Daniele, Morgagni, Paolo, Cipollari, Chiara, Vittimberga, Giovanni, Framarini, Massimo, Cozzaglio, Luca, Pedrazzani, Corrado, Berardi, Stefano, Baiocchi, Gian Luca, Roviello, Franco, Portolani, Nazario, de Manzoni, Giovanni, Costamagna, Guido, Doglietto, Giovanni Battista, and Pacelli, Fabio

Published
2016
Full Text
View/download PDF

26. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference

Author

Baiocchi, Gian Luca, D’Ugo, Domenico, Coit, Daniel, Hardwick, Richard, Kassab, Paulo, Nashimoto, Atsushi, Marrelli, Daniele, Allum, William, Berruti, Alfredo, Chandramohan, Servarayan Murugesan, Coburn, Natalie, Gonzàlez-Moreno, Santiago, Hoelscher, Arnulf, Jansen, Edwin, Leja, Marcis, Mariette, Christophe, Meyer, Hans-Joachim, Mönig, Stefan, Morgagni, Paolo, Ott, Katia, Preston, Shaun, Rha, Sun Young, Roviello, Franco, Sano, Takeshi, Sasako, Mitsuru, Shimada, Hideaki, Schuhmacher, Cristoph, So Bok-yan, Jimmy, Strong, Vivian, Yoshikawa, Takaki, Terashima, Masanori, Ter-Ovanesov, Michail, Van der Velde, Cornelis, Memo, Maurizio, Castelli, Francesco, Pecorelli, Sergio, Detogni, Claudio, Kodera, Yasuhiro, and de Manzoni, Giovanni

Published
2016
Full Text
View/download PDF

27. Surgical management of duodenal stump fistula after elective gastrectomy for malignancy: an Italian retrospective multicenter study

Author

Cozzaglio, Luca, Giovenzana, Marco, Biffi, Roberto, Cobianchi, Lorenzo, Coniglio, Arianna, Framarini, Massimo, Gerard, Leonardo, Gianotti, Luca, Marchet, Alberto, Mazzaferro, Vincenzo, Morgagni, Paolo, Orsenigo, Elena, Rausei, Stefano, Romano, Fabrizio, Rosa, Fausto, Rosati, Riccardo, Roviello, Francesco, Sacchi, Matteo, Morenghi, Emanuela, and Quagliuolo, Vittorio

Published
2016
Full Text
View/download PDF

28. Open versus laparoscopic gastrectomy for advanced gastric cancer: a propensity score matching analysis of survival in a western population-on behalf of the Italian Research Group for Gastric Cancer

Author

Lombardi, P. M., Bernasconi, D., Baiocchi, G. L., Berselli, M., Biondi, Alberto, Castoro, C., Catarci, Marco, Degiuli, M., Fumagalli Romario, U., Giacopuzzi, S., Marchesi, F., Marrelli, D., Mazzola, M., Molfino, S., Olmi, S., Rausei, S., Rosa, Fausto, Rosati, R., Roviello, F., Santi, Samuele, Solaini, L., Staderini, F., Vigano, J., Ferrari, G., Agnes, Annamaria, Alfieri, Sergio, Alloggio, M., Bencivenga, M., Benedetti, M., Bottari, A., Cianchi, F., Cocozza, E., Dalmonte, G., De Martini, P., De Pascale, S., Desio, M., Emiliani, G., Ercolani, G., Galli, F., Garosio, I., Giani, A., Gualtierotti, M., Marano, L., Morgagni, P., Peri, A., Puccetti, F., Reddavid, R., Uccelli, M., Biondi A. (ORCID:0000-0002-2470-7858), Catarci M., Rosa F. (ORCID:0000-0002-7280-8354), Santi S., Agnes A., Alfieri S. (ORCID:0000-0002-0404-724X), Lombardi, P. M., Bernasconi, D., Baiocchi, G. L., Berselli, M., Biondi, Alberto, Castoro, C., Catarci, Marco, Degiuli, M., Fumagalli Romario, U., Giacopuzzi, S., Marchesi, F., Marrelli, D., Mazzola, M., Molfino, S., Olmi, S., Rausei, S., Rosa, Fausto, Rosati, R., Roviello, F., Santi, Samuele, Solaini, L., Staderini, F., Vigano, J., Ferrari, G., Agnes, Annamaria, Alfieri, Sergio, Alloggio, M., Bencivenga, M., Benedetti, M., Bottari, A., Cianchi, F., Cocozza, E., Dalmonte, G., De Martini, P., De Pascale, S., Desio, M., Emiliani, G., Ercolani, G., Galli, F., Garosio, I., Giani, A., Gualtierotti, M., Marano, L., Morgagni, P., Peri, A., Puccetti, F., Reddavid, R., Uccelli, M., Biondi A. (ORCID:0000-0002-2470-7858), Catarci M., Rosa F. (ORCID:0000-0002-7280-8354), Santi S., Agnes A., and Alfieri S. (ORCID:0000-0002-0404-724X)

Abstract

Background Oncologic outcomes after laparoscopic gastrectomy for advanced gastric cancer in the West have been poorly investigated. The aim of the present study was to compare survival outcomes in patients undergoing curative-intent laparoscopic and open gastrectomy for advanced gastric cancer in several centres belonging to the Italian Research Group for Gastric Cancer. Methods Data of patients operated between 2015 and 2018 were retrospectively analysed. Propensity Score Matching was performed to balance baseline characteristics of patients undergoing laparoscopic and open gastrectomy. The primary endpoint was 3-year overall survival. Secondary endpoints were 3-year disease-free survival and short-term outcomes. Multivariable regression analyses for survival were conducted. Results Data were retrieved from 20 centres. Of the 717 patients included, 438 patients were correctly matched, 219 per group. The 3-year overall survival was 73.6% and 68.7% in the laparoscopic and open group, respectively (p = 0.40). When compared with open gastrectomy, laparoscopic gastrectomy showed comparable 3-year disease-free survival (62.8%, vs 58.9%, p = 0.40), higher rate of return to intended oncologic treatment (56.9% vs 40.2%, p = 0.001), similar 30-day morbidity/mortality. Prognostic factors for survival were ASA Score >= 3, age-adjusted Charlson Comorbidity Index >= 5, lymph node ratio >= 0.15, p/ypTNM Stage III and return to intended oncologic treatment. Conclusions Laparoscopic gastrectomy for advanced gastric cancer offers similar rates of survival when compared to open gastrectomy, with higher rates of return to intended oncologic treatment. ASA score, age-adjusted Charlson Comorbidity Index, lymph node ratio, return to intended oncologic treatment and p/ypTNM Stage, but not surgical approach, are prognostic factors for survival.

Published
2022

29. Consequences of the COVID-19 pandemic on the diagnosis and treatment of gastric cancer in referral centers in Italy

Author

Solaini, L., Bencivenga, M., Rosa, Fausto, D'Ignazio, A., Marino, E., Ministrini, S., Sofia, S., Sacco, M., Mura, G., Rausa, E., Prizio, M. D., Graziosi, L., Degiuli, M., Tiberio, G. A. M., Alfieri, Sergio, Marrelli, D., Morgagni, P., Ercolani, G., Rosa F. (ORCID:0000-0002-7280-8354), Alfieri S. (ORCID:0000-0002-0404-724X), Solaini, L., Bencivenga, M., Rosa, Fausto, D'Ignazio, A., Marino, E., Ministrini, S., Sofia, S., Sacco, M., Mura, G., Rausa, E., Prizio, M. D., Graziosi, L., Degiuli, M., Tiberio, G. A. M., Alfieri, Sergio, Marrelli, D., Morgagni, P., Ercolani, G., Rosa F. (ORCID:0000-0002-7280-8354), and Alfieri S. (ORCID:0000-0002-0404-724X)

Abstract

Background: The coronavirus pandemic had a major impact in Italy. The Italian health system’s re-organization to face the emergency may have led to significant consequences especially in the diagnosis and treatment of malignancies. This study aimed to assess the impact of the pandemic in the diagnosis and treatment of gastric cancer in nine Gruppo Italiano RIcerca Cancro Gastrico (GIRCG) centers. Methods: All patients assessed for gastric adenocarcinoma at nine GIRCG centers between January 2019 and November 2020 were included. Patients were grouped according to the date of “patient 1’s” diagnosis in Italy: preCOVID versus COVID. Clinico-pathological and outcome differences between the two groups were analyzed. Results: A total of 632 patients were included in the analysis (205 in the COVID group). The cT4 weighted ratios were higher in 2020 from April to September, with the greatest differences in May, August and September. The cM+ weighted ratio was significantly higher in July 2020. The mean number of gastrectomies had the greatest reduction in March and May 2020 compared with 2019. The median times from diagnosis to chemotherapy, to complete diagnostic work-up or to operation were longer in 2019. The median time from the end of chemotherapy to surgery was 17 days longer in the preCOVID group. Conclusions: A greater number of advanced or metastatic cases were diagnosed after the spread of SARS-CoV-2 infection, especially after the “full lockdown” periods. During the pandemic, once gastric cancer patients were referred to one of the centers, a shorter time to complete the diagnostic work-up or to address them to the best treatment option was required.

Published
2022

32. 62: WHICH GASTRIC CANCER PATIENTS COULD BENEFIT FROM STAGING LAPAROSCOPY? A GIRCG MULTICENTER COHORT STUDY

Author

Solaini, L, primary, Bencivenga, M, additional, D’Ignazio, A, additional, Milone, M, additional, Marino, E, additional, De Pascale, S, additional, Rosa, F, additional, Sacco, M, additional, Fumagalli Romario, U, additional, Graziosi, L, additional, De Palma, G, additional, Marrelli, D, additional, Morgagni, P, additional, and Ercolani, G, additional

Published
2022
Full Text
View/download PDF

33. Surgical management of oncologic patient during and after the COVID-19 outbreak: practical recommendations from the Italian society of Surgical Oncology

Author

Cavaliere, D., Parini, D., Marano, L., Cipriani, F., Di Marzo, F., Macri, A., D'Ugo, D., Roviello, F., Gronchi, A., Lorenzon, L., De Luca, R., Boggi, U., Torzilli, G., Folli, S., Restivo, A., Spolverato, G., Garofalo, A., Lissidini, G., Dessena, M., Girelli, R., Sorrenti, S., Fumagalli Romario, U., Morgagni, P., Rastrelli, M., Cananzi, F., Degiuli, M., Simone, M., Donini, A., Muratore, A., Belluco, C., Ercolani, G., Cavaliere D., Parini D., Marano L., Cipriani F., Di Marzo F., Macri A., D'Ugo D., Roviello F., Gronchi A., Lorenzon L., De Luca R., Boggi U., Torzilli G., Folli S., Restivo A., Spolverato G., Garofalo A., Lissidini G., Dessena M., Girelli R., Sorrenti S., Fumagalli Romario U., Morgagni P., Rastrelli M., Cananzi F., Degiuli M., Simone M., Donini A., Muratore A., Belluco C., and Ercolani G.

Subjects
medicine.medical_specialty, Telemedicine, medicine.medical_treatment, Scientific literature, Recommendations, Rationalization (economics), Phase (combat), Cancer, COVID-19, Oncologic surgery, Multidisciplinary approach, Surgical oncology, Neoplasms, Pandemic, Medicine, Humans, Neoadjuvant therapy, COVID-19 · Cancer, Infection Control, business.industry, Patient Selection, COVID-19 · Cancer, Recommendations, Oncologic surgery, medicine.disease, Surgery, Surgical Oncology, Italy, Practice Guidelines as Topic, Original Article, Medical emergency, business
Abstract

The recent outbreak of COVID-19 in Italy caused a limitation of the resources of the health system, which necessarily led to their rationalization in the critical phase (phase 1) and a reorganization of the system in the following phase (phase 2). The Italian Society of Oncological Surgery–SICO has drafted these practical recommendations, calibrated on the most recent scientific literature and taking into account current health regulations and common sense. Surgical activity during phase 1 and 2 should follow a dynamic model, considering architectural structures, hospital mission, organizational models. Surgical delay should not affect oncological prognosis. However, COVID-19-positive cancer patients should be postponed until the infection is cured. The patients to consider more carefully before delaying surgery are those who have completed neoadjuvant therapy, patients with high biological aggressiveness tumors or without therapeutic alternatives. The multidisciplinary discussions are fundamental for sharing clinical decisions; videoconference meetings are preferable and use of telemedicine for follow-up is recommended. Especially in phase 1, maximum effort must be made to reduce the spread of the pandemic. Prefer intra-corporeal rather than open anastomosis during laparoscopy and mechanical rather than hand-sewn anastomosis in open surgery. Consider PPE for caregivers during stoma management. Minimal invasive surgery is not discouraged, because there is little evidence for augmented risk. Specific procedures have to be followed and use of energy devices has to be limited. Training programs with COVID-19 + patients are not recommended. All staff in OR should be trained with specific courses on specific PPE use. Differentiate recommendations are presented for every district cancer. Surgical oncology during phase 2 should be guaranteed by individual and distinct protocols and pathways between cancer patients and COVID-19 + patients with resources specifically addressed to the two distinct kind of patients to limit diagnostic/therapeutic interferences or slowdowns. These recommendations are based on currently available evidence about management of oncologic patients during COVID-19 pandemic, were endorsed by the SICO Executive Board, and are considered suitable for nationwide diffusion. They will be subject to updates and revisions in case of new and relevant scientific acquisitions.

Published
2021

37. Follow-Up After Gastrectomy for Cancer: An Appraisal of the Italian Research Group for Gastric Cancer

Author

Baiocchi, Gian Luca, Marrelli, Daniele, Verlato, Giuseppe, Morgagni, Paolo, Giacopuzzi, Simone, Coniglio, Arianna, Marchet, Alberto, Rosa, Fausto, Capponi, Michela Giulii, Di Leo, Alberto, Saragoni, Luca, Ansaloni, Luca, Pacelli, Fabio, Nitti, Donato, D’Ugo, Domenico, Roviello, Franco, Tiberio, Guido A. M., Giulini, Stefano M., and De Manzoni, Giovanni

Published
2014
Full Text
View/download PDF

38. The SIC-GIRCG 2013 Consensus Conference on Gastric Cancer

Author

De Manzoni, Giovanni, Baiocchi, Gian Luca, Framarini, Massimo, De Giuli, Maurizio, D’Ugo, Domenico, Marchet, Alberto, Nitti, Donato, Marrelli, Daniele, Morgagni, Paolo, Rinnovati, Andrea, Rosati, Riccardo, Roviello, Franco, Allieta, Rosaldo, Berti, Stefano, Bracale, Umberto, Capelli, Patrizio, Cavicchi, Angelo, Di Martino, Natale, Donini, Annibale, Filippini, Angelo, Francioni, Gianfranco, Frascio, Marco, Garofalo, Alfredo, Giulini, Stefano Maria, Grassi, Giovanni Battista, Innocenti, Paolo, Martino, Antonio, Mazzocconi, Gualtiero, Mazzola, Lorenzo, Montemurro, Severino, Palasciano, Nicola, Pantuso, Gianni, Pernthaler, Heinrich, Petri, Roberto, Piazza, Diego, Sacco, Rosario, Sgroi, Giovanni, Staudacher, Carlo, Testa, Michele, Vallicelli, Carlo, Vettoretto, Nereo, Zingaretti, Costantino, Capussotti, Lorenzo, Morino, Mario, and Verdecchia, Giorgio Maria

Published
2014
Full Text
View/download PDF

39. Core Outcome Set for Surgical Trials in Gastric Cancer (GASTROS Study):International patient and healthcare professional consensus

Author

Alkhaffaf, B, Metryka, A, Blazeby, J M, Glenny, A-M, Adeyeye, A, Costa, P M, Diez Del Val, I, Gisbertz, S S, Guner, A, Law, S, Lee, H-J, Li, Z, Nakada, K, Reim, D, Vorwald, P, Baiocchi, G L, Allum, W, Chaudry, M A, Griffiths, E A, Williamson, P R, Bruce, I A, Li, S., He, Yl, Xu, Z., Xue, Y., Liang, H., Li, G., Zhao, E., Neumann, P., O’Neill, L., Guinan, E., Zanotti, D., de Manzoni, G., Hagens, Erc., van Berge Henegouwen, Mi., Lages, P., Onofre, S., Restrepo Nunez, Rm., Salcedo Cabanas, G., Posada Gonzalez, M., Marin Campos, C., Candas, B., Emre Baki, B., Selim Bodur, M., Yildirim, R., Burak Cekic, A., Brown, J., Hayes, K., Daher, I., Gianchandani Moorjani, Rh., Adetoyese Adeyeye, A., Sulaiman Olayide, A., Mitsuo Leon-Takahashi, A., Pueyo Rabanal, A., Peri, A., Boddy, A., Novotny, A., Charalabopoulos, A., Alemdar, A., Souadka, A., Rodrigues Gomes, Am., Lazaro, A., Maciel Da Silva, A., do Rosario da Conceicao Silva e Santos, A., Guidi, A., Silva Bernardes, Aj., Quinn, A., Isik, A., A Slipek, A., Candas Altinbas, B., Johnson Alegbeleye, B., Wool Eom, B., Frittoli, B., Lonsdale, B., Rogers, B., Ammori, Bj., Rau, B., Molteni, B., Byrne, Be., Villacıs- Bermeo, Ba., Villacıs Gallardo, Be., Kose, B., Sampedro Nogueira, Cj., Loureiro, C., Oliveira de Sousa, Cm., Collins, Cg., Nonso Ekwunife, C., Chukwunwendu Osuagwu, C., Wong, Cly., Winkler, C., Reim, D., Kjær, Dw., Cooper, D., Horner, D., Irvine, D., Bowrey, Dj., Chuter, Dj., Elliot, D., Mcghee, D., Toth, D., Ofner, D., Manatakis, Dk., Silveira Martins, Dr., Belt, Ejt., Cattaneo, E., Samadov, E., Colak, E., Treppiedi, E., Guglielmi, E., Redondo- Villahoz, E., Ciferri, E., Tiemens-de Graaf, E., Cocozza, E., Pape, E., Drozdov, Es., Enrico, F., Rashid, F., Sandri, Marco, Rosa, F., Mingol Navarro, F., Simionato Perrotta, F., Chan, Fsy., Saavedra Tomasich, Fd., Takeda, Fr., Farrell, F., Olanike Wuraola, F., Rosero, G., Bevilacqua, G., Baronio, G., Mura, G., D’Eugenio, G., Ortega-Perez, G., Tilt, G., Sutcliffe, G., Mureddu, G., Guerra Jacob, G., Daneri, H., Olufemi Gbenga, H., Okabe, H., Kingsford Smith, I., Olawale Lateef, I., Garosio, I., Hatipoglu, I., Gockel, I., Negoi, I., Min, Ish., Mesquita, Imm., Diez del Val, I., Leemhuis, Jhf., Gossage, Ja., Weindelmayer, J., Izbicki, Jr., McKenzie Manson, J., Kelly, J., Stoot, Jhmb., Haveman, Jw., Brown, Jd., Sultan, J., Hassall, J., van Sandick, J., Saunders, Jh., Clarke, Jk., Heisterkamp, J., Vargas, Ji., Couselo Villanueva, Jm., Ingmire, J., Mcewen, J., Galindo Alvarez, J., Turner, J., Peng, J., Roberts, K., Brandon, Kg., Mitchell, K., Mccarthy, K., Akhtar, K., Mikhailovich, Kn., Corbelli, L., Medeiros Milhomem, L., Solaini, L., Fengyuan, L., Xinchun, L., Timmermans, L., Porritt, L., Taglietti, L., Bonavina, L., F. Pinheiro L., de los Angeles Mayo Ossorio, M., Schiavo, M., Marchesiello, M., das Dores Vieira Leite, M., Demois, M., Di Felice, Mt., de Sousa, Md., Takahashi, M., Forshaw, M., Berselli, M., Paro, M., Usta, Ma., Yan, Mh., Pinchin, M., Caprioli, M., Rubbini, M., Cowen, M., Herrera Servin, Ma., Li, Mz., Sasako, M., Shukri Jahit, M., Ngonyoku Muhinga, M., Tareen, Ma., Ahmad, Mf., Bodur, Ms., Kaban, M., Farooq, N., Coburn, N., Cooper, N., Blencowe, Ns., Loria, N., de Vries, N., Adami Andreollo, N., Koksal, N., Zanini, N., Kreuser, N., Okkabaz, N., Damiana, O., Afuwape, O., Kayode Fasiku, O., Comensoli, O., F. Koroye O., Capener, P., Morgagni, P., Pernadas Lages, Pm., Wilkerson, Pm., Turner, P., Dutton, P., Hayes, P., Vorwald, P., Singh, P., Gan, Q., Kottayasamy Seenivasagam, R., Ayloor Seshadri, R., Guevara Castro, R., Douglas, R., Koshy, Rm., Yıldırım, R., Skipworth, Rje., Gould, Ra., Wetherill, Rc., Shaw, R., Burley, Ra., Palatucci, R., Racalbuto, R., Correia Casaca, Rm., Lagarde, Sm., Gana, S., Marietti, S., Qureshi, S., Morales-Conde, S., Molfino, S., Barreto, Sg., Turkyilmaz, S., Turan-Trabzon, S., Frisch, S., Castoldi, S., Belloni, S., Flisi, S., Galloway, S., Maria, Sr., Royston, S., Boyle, T., Sezer, T., Mengardo, V., Concepcion Martın, V., Lee Wills, V., Owen-Holt, V., Casagrande, V., Al-Khyatt, W., Jansen, W., Wang, W., Eshuis, W., Polkowski, Wp., Huang, X., Wang, X., Chen, Xz., Gonzalez Dominguez, Y., Wang, Y., Viswanath, Yks., He, Yl., Demir, Z., Na, Z., Surgery, CCA - Cancer Treatment and Quality of Life, CCA - Cancer biology and immunology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Imaging and biomarkers, Experimental Immunology, Clinical Immunology and Rheumatology, CCA -Cancer Center Amsterdam, and CCA - Cancer Treatment and quality of life

Subjects
medicine.medical_specialty, Manchester Cancer Research Centre, business.industry, gastric cancer, ResearchInstitutes_Networks_Beacons/mcrc, Delphi method, MEDLINE, Cancer, medicine.disease, Outcome (game theory), 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), 030220 oncology & carcinogenesis, Family medicine, gastros, Medicine, Surgery, 030212 general & internal medicine, Stage (cooking), Adverse effect, business, Set (psychology)
Abstract

Background Surgery is the primary treatment that can offer potential cure for gastric cancer, but is associated with significant risks. Identifying optimal surgical approaches should be based on comparing outcomes from well designed trials. Currently, trials report different outcomes, making synthesis of evidence difficult. To address this, the aim of this study was to develop a core outcome set (COS)—a standardized group of outcomes important to key international stakeholders—that should be reported by future trials in this field. Methods Stage 1 of the study involved identifying potentially important outcomes from previous trials and a series of patient interviews. Stage 2 involved patients and healthcare professionals prioritizing outcomes using a multilanguage international Delphi survey that informed an international consensus meeting at which the COS was finalized. Results Some 498 outcomes were identified from previously reported trials and patient interviews, and rationalized into 56 items presented in the Delphi survey. A total of 952 patients, surgeons, and nurses enrolled in round 1 of the survey, and 662 (70 per cent) completed round 2. Following the consensus meeting, eight outcomes were included in the COS: disease-free survival, disease-specific survival, surgery-related death, recurrence, completeness of tumour removal, overall quality of life, nutritional effects, and ‘serious’ adverse events. Conclusion A COS for surgical trials in gastric cancer has been developed with international patients and healthcare professionals. This is a minimum set of outcomes that is recommended to be used in all future trials in this field to improve trial design and synthesis of evidence.

Published
2021

41. Updates on Surgical Management of Advanced Gastric Cancer: New Evidence and Trends. Insights from the First International Course on Upper Gastrointestinal Surgery—Varese (Italy), December 2, 2011

Author

Rausei, Stefano, Dionigi, Gianlorenzo, Sano, Takeshi, Sasako, Mitsuru, Biondi, Alberto, Morgagni, Paolo, Garofalo, Alfredo, Boni, Luigi, Frattini, Francesco, D’Ugo, Domenico, Preston, Shaun, Marrelli, Daniele, Degiuli, Maurizio, Capella, Carlo, Sacco, Rosario, Ruspi, Laura, De Manzoni, Giovanni, Roviello, Franco, Pinotti, Graziella, Rovera, Francesca, Noh, Sung Hoon, Coit, Daniel, and Dionigi, Renzo

Published
2013
Full Text
View/download PDF

46. Consequences of the COVID-19 pandemic on the diagnosis and treatment of gastric cancer in referral centers in Italy

Author

Solaini, Leonardo, Bencivenga, Maria, Rosa, Fausto, D’ignazio, Alessia, Marino, Elisabetta, Ministrini, Silvia, Sofia, Silvia, Sacco, Michele, Mura, Gianni, Rausa, Emanuele, Prizio, Marco De, Graziosi, Luigina, Degiuli, Maurizio, Tiberio, Guido Alberto Massimo, Alfieri, Sergio, Marrelli, Daniele, Morgagni, Paolo, and Ercolani, Giorgio

Abstract

Background: The coronavirus pandemic had a major impact in Italy. The Italian health system’s re-organization to face the emergency may have led to significant consequences especially in the diagnosis and treatment of malignancies. This study aimed to assess the impact of the pandemic in the diagnosis and treatment of gastric cancer in nine Gruppo Italiano RIcerca Cancro Gastrico (GIRCG) centers.Methods: All patients assessed for gastric adenocarcinoma at nine GIRCG centers between January 2019 and November 2020 were included. Patients were grouped according to the date of “patient 1’s” diagnosis in Italy: preCOVID versus COVID. Clinico-pathological and outcome differences between the two groups were analyzed.Results: A total of 632 patients were included in the analysis (205 in the COVID group). The cT4 weighted ratios were higher in 2020 from April to September, with the greatest differences in May, August and September. The cM+ weighted ratio was significantly higher in July 2020. The mean number of gastrectomies had the greatest reduction in March and May 2020 compared with 2019. The median times from diagnosis to chemotherapy, to complete diagnostic work-up or to operation were longer in 2019. The median time from the end of chemotherapy to surgery was 17 days longer in the preCOVID group.Conclusions: A greater number of advanced or metastatic cases were diagnosed after the spread of SARS-CoV-2 infection, especially after the “full lockdown” periods. During the pandemic, once gastric cancer patients were referred to one of the centers, a shorter time to complete the diagnostic work-up or to address them to the best treatment option was required.

Published
2023
Full Text
View/download PDF

47. Virtual reality study of the effects of railway crossing safety technologies on pedestrian behaviour

Author

Aupetit, Samuel, Escaich, Sara, Gillet, Camille, Herber, Philippe, Grison, Elise, and Morgagni, Simone

Abstract

This study reports on the description of an evaluation of safety systems at Pedestrian Track Crossings (PTC) in French train stations installed to cross over tracks when no other installation is deployed. Two complementary systems - a physical chicane positioned before the crossing zone and a ringing alarm - have been proposed in addition to the existing flashing pictogram. A study, combining a quantitative experimental setup using virtual reality to measure the efficacy of the systems, and a qualitative ergonomic analysis method to complete the results, was proposed to 100 participants. Our results allow us to measure the effect of safety systems on participants’ crossing behaviour, gaze, and kinematic. It appears that the combination with the ringing alarm led to more safety behaviours. Moreover, qualitative data gave new perspectives to improve the system tested and make PTC safer.

Published
2023
Full Text
View/download PDF

49. Which gastric cancer patients could benefit from staging laparoscopy? A GIRCG multicenter cohort study.

Author

Solaini, Leonardo, Bencivenga, Maria, D'ignazio, Alessia, Milone, Marco, Marino, Elisabetta, De Pascale, Stefano, Rosa, Fausto, Sacco, Michele, Fumagalli Romario, Uberto, Graziosi, Luigina, De Palma, Giovanni, Marrelli, Daniele, Morgagni, Paolo, and Ercolani, Giorgio

Subjects
STOMACH cancer, CANCER patients, LAPAROSCOPY, PERITONEAL cancer, COHORT analysis, INTESTINAL tumors
Abstract

This study aimed to investigate which gastric cancer patients could benefit the most from staging laparoscopy. A retrospective cohort study was carried out, including 316 (216 cM- and 100 cM+) gastric cancer patients who had undergone staging laparoscopy between 2010 and 2020 in seven GIRCG centers. A model including easily-accessible clinical, biochemical and pathological markers was constructed to predict the risk of carcinomatosis. ROC curve and decision curve analyses were used to verify its accuracy and net benefit. In the cM-population staging laparoscopy could detect 67 cases who had peritoneal carcinomatosis or positive cytology, for a yield of 30.5%. In cM-patients, intestinal type tumors (0.25, 0.12–0.51; p = 0.002), cT4 tumors (2.18, 1.11–4.28; p = 0.023) and cancers of the lower third (0.31, 0.14–0.70; p = 0.004) were associated with the presence of peritoneal carcinomatosis and/or positive cytology. The ROC curve analysis of the model including the three variables showed an AUC of 0.75 (0.68–0.81, p < 0.001). The decision curve analyses showed that the model had a higher net benefit than the treating all strategy between threshold probabilities of 15 and 50%. Staging laparoscopy is a useful tool to address the patient with gastric cancer to the most adequate treatment. In cM-patients the assessment of the location of the tumor, the Lauren's histotype and the cT status may help in providing additional elements in indicating or not the use of staging laparoscopy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results